Bruch, L.A., Hill, D.A., Cai, D.X., Levy, B.K., Dehner, L.P. and Perry, A. (2001) A Role for Fluorescence in Situ Hybridization Detection of Chromosome 22q Dosage in Distinguishing Atypical Teratoid/Rhabdoid Tumors from Medulloblastoma/Central Primitive Neuroectodermal Tumors. Human Pathology, 32, 156-162.
https://doi.org/10.1053/hupa.2001.21572

has been cited by the following article:

• TITLE: Cure of Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System: A Case Report

  AUTHORS: Chengming Xu, Congyan Wu, Meiqing Lou, Yaodong Zhao

  KEYWORDS: Atypical Teratoid/Rhabdoid Tumor, Case Report

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.9 No.1, December 31, 2019

  ABSTRACT: Atypical teratoid/rhabdoid tumor (AT/RT) is an embryonic central nervous system tumor. It has a low incidence with a high degree of malignancy and a poor prognosis. Five years ago, we successfully treated a child with AT/RT. Treatment comprised total tumor resection, 6 MV X 3D conformal radiotherapy (DT: 36Gy/18FX) and six courses of chemotherapy, including teniposide 25 mg (qd × 5d), ACNU 25 mg (qd × 1d), vincristine 1 mg (qd × 1d). There was no tumor recurrence after 5 years of follow-up. We adjusted the previous AT/RT regimen to make it more suitable for the individual treatment of this patient, and now the patient has achieved a cure. So we think this regimen is effective and it is worthy of recommendation.